Amicus Therapeutics Stock Price on March 6, 2024

FOLD Stock  USD 9.96  0.09  0.91%   
Below is the normalized historical share price chart for Amicus Therapeutics extending back to May 31, 2007. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of Amicus Therapeutics stands at 9.96, as last reported on the 28th of November, with the highest price reaching 10.07 and the lowest price hitting 9.81 during the day.
IPO Date
31st of May 2007
200 Day MA
10.9307
50 Day MA
10.7688
Beta
0.673
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
If you're considering investing in Amicus Stock, it is important to understand the factors that can impact its price. Amicus Therapeutics secures Sharpe Ratio (or Efficiency) of -0.0834, which signifies that the company had a -0.0834% return per unit of risk over the last 3 months. Amicus Therapeutics exposes twenty-three different technical indicators, which can help you to evaluate volatility embedded in its price movement. Please confirm Amicus Therapeutics' Mean Deviation of 1.57, standard deviation of 2.51, and Risk Adjusted Performance of (0.05) to double-check the risk estimate we provide.
  
At present, Amicus Therapeutics' Common Stock Shares Outstanding is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 3 B, whereas Capital Stock is forecasted to decline to about 2.9 M. . At present, Amicus Therapeutics' Price Earnings To Growth Ratio is projected to increase slightly based on the last few years of reporting. The current year's Price To Book Ratio is expected to grow to 27.46, whereas Price Earnings Ratio is projected to grow to (26.25). Amicus Stock price history is provided at the adjusted basis, taking into account all of the recent filings.

Sharpe Ratio = -0.0834

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskAverage RiskHigh RiskHuge Risk
Negative ReturnsFOLD

Estimated Market Risk

 2.51
  actual daily
22
78% of assets are more volatile

Expected Return

 -0.21
  actual daily
0
Most of other assets have higher returns

Risk-Adjusted Return

 -0.08
  actual daily
0
Most of other assets perform better
Based on monthly moving average Amicus Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Amicus Therapeutics by adding Amicus Therapeutics to a well-diversified portfolio.
Price Book
16.6426
Enterprise Value Ebitda
(35.99)
Price Sales
6.0285
Shares Float
241.1 M
Wall Street Target Price
17.75

Related Headline

Cytokinetics Headline on 6th of March 2024

Filed transaction by Cytokinetics Officer: Evp, Chief Commercial Officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)

Amicus Therapeutics Valuation on March 6, 2024

It is possible to determine the worth of Amicus Therapeutics on a given historical date. On March 6, 2024 Amicus was worth 13.49 at the beginning of the trading date compared to the closed value of 12.6. We use multiple weighted factors in our valuation methodologies to arrive at the intrinsic value of Amicus Therapeutics stock. Still, in general, we apply an absolute valuation method to find Amicus Therapeutics' value based on its fundamental and technical indicators available within our service. As compared to an absolute model, our relative valuation model uses a comparative analysis of Amicus Therapeutics where we calculate exposure to its market risk and evaluate relevant financial multiples and ratios against Amicus Therapeutics' related companies.
 Open High Low Close Volume
  13.40    13.53    13.19    13.35    2,072,621  
03/06/2024
  13.49    13.49    12.37    12.60    3,755,164  
  12.66    12.76    12.26    12.29    5,597,635  
Backtest Amicus Therapeutics  |  Amicus Therapeutics History  |  Amicus Therapeutics Valuation   PreviousNext  
Open Value
13.49
12.6
Closing Value
21.02
Upside

Amicus Therapeutics Trading Date Momentum on March 6, 2024

On March 07 2024 Amicus Therapeutics was traded for  12.29  at the closing time. The top price for the day was 12.76  and the lowest listed price was  12.26 . The trading volume for the day was 5.6 M. The trading history from March 7, 2024 was a factor to the next trading day price decrease. The overall trading delta against the next closing price was 2.46% . The overall trading delta against the current closing price is 8.97% .

Amicus Therapeutics Fundamentals Correlations and Trends

By evaluating Amicus Therapeutics' financials over time, investors can gain insight into future company performance. However, you can also analyze the published financial statements to find patterns among Amicus Therapeutics' main balance sheet or income statement drivers and many other relevant indicators that can statistically be found significantly correlated or uncorrelated. Amicus financial account trend analysis is a perfect complement when working with valuation or volatility modules.

About Amicus Therapeutics Stock history

Amicus Therapeutics investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for Amicus is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in Amicus Therapeutics will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing Amicus Therapeutics stock prices may prove useful in developing a viable investing in Amicus Therapeutics
Last ReportedProjected for Next Year
Common Stock Shares Outstanding295.2 M309.9 M
Net Loss-212.9 M-223.6 M

Amicus Therapeutics Quarterly Net Working Capital

340.34 Million

Amicus Therapeutics Stock Technical Analysis

Amicus Therapeutics technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Amicus Therapeutics technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Amicus Therapeutics trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

Price Boundaries

Amicus Therapeutics Period Price Range

Low
November 28, 2024
0.00  NaN%
High

 0.00 

     

 0.00 

Amicus Therapeutics cannot be verified against its exchange. Please verify the symbol is currently traded on NASDAQ Exchange. If you still believe the symbol you are trying to look up is valid, please let us know, and we will check it as soon as possible.

Amicus Therapeutics November 28, 2024 Market Strength

Market strength indicators help investors to evaluate how Amicus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Amicus Therapeutics shares will generate the highest return on investment. By undertsting and applying Amicus Therapeutics stock market strength indicators, traders can identify Amicus Therapeutics entry and exit signals to maximize returns

Amicus Therapeutics Technical and Predictive Indicators

Predictive indicators are helping investors to find signals for Amicus Therapeutics' price direction in advance. Along with the technical and fundamental analysis of Amicus Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of Amicus to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.

Complementary Tools for Amicus Stock analysis

When running Amicus Therapeutics' price analysis, check to measure Amicus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Amicus Therapeutics is operating at the current time. Most of Amicus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Amicus Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Amicus Therapeutics' price. Additionally, you may evaluate how the addition of Amicus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Portfolio Holdings
Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments